Mar
18
2020
On demand

Enabling new cell therapies with GMP-compliant multiparametric cell sorting

While effective protocols for the isolation and expansion of pan T cells for adoptive cell therapies have been developed over the past decade, many challenges persist in using other effector cells, such as: antigen-specific T Cells, tumor-infiltrating lymphocytes (TILs), or mesenchymal stem cells (MSCs). One such challenge is the lack of a GMP-compliant platform for multiparametric enrichment of these cells.

As treatments with these cell types for solid tumors and non-malignant diseases become more prevalent, improving the processes governing their enrichment will help the clinical translation of new therapies.

In this roundtable discussion, we will look at how a GMP-compliant flow cytometry-based cell sorting platform, the MACSQuant® Tyto® Cell Sorter, helps scientists in clinical and commercial settings enrich cells for use in clinical trials and research.

After an introduction of this new technology, key opinion leaders will share their experiences using the MACSQuant Tyto Cell Sorter.

Attendees learn:

  • Which new options are available for the enrichment of effector cells for clinical use in adoptive cell therapies
  • The benefits of the MACSQuant® Tyto® cell sorting technology and associated GMP-grade consumables and reagents
  • How the system helps advance clinical trials and clinical research in commercial and academic settings




Steve Elliman
CSO at Orbsen Therapeutics Ltd
Ivy Lai
Lab Manager at MD Anderson Cancer Center
Dr Sandy Pelletier
Scientific Coordinator, Adoptive Cell Transfer (ACT) Immunotherapy Program, Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM)
Jack Dunne
Consultant at Miltenyi Biotec
Felix Eppler, PhD
Group Leader, Cell Sorting Product Management, Miltenyi Biotec

SPEAKERS

Steve Elliman
CSO at Orbsen Therapeutics Ltd
Ivy Lai
Lab Manager at MD Anderson Cancer Center
Dr Sandy Pelletier
Scientific Coordinator, Adoptive Cell Transfer (ACT) Immunotherapy Program, Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM)
Jack Dunne
Consultant at Miltenyi Biotec
Felix Eppler, PhD
Group Leader, Cell Sorting Product Management, Miltenyi Biotec

You might also like

Thinking translational: Things to consider in CAR T cell research workflows

S Rösch, PhD
Saskia Rösch, PhD
Saskia Rösch, PhD
Global Product Manager at Miltenyi Biotec
22 Jun 2022
35
Days
0
Hrs
22
Min
Register

Accelerating cell therapy discovery & development with non-viral gene...

D Hermanson
X Patrinostro
David Hermanson
David Hermanson
Senior Manager of R&D Applications, Cell and Gene Therapy at Bio-techne
Xiaobai Patrinostro
Xiaobai Patrinostro
Manager of Genome Engineering Services, Cell and Gene Therapy at Bio-techne
16 Jun 2022
28
Days
8
Hrs
22
Min
Register

Overcoming current challenges in immunotherapy drug development with...

S F. Boj
Sylvia  F. Boj
Sylvia F. Boj
Chief Scientific Officer at Hubrecht Institute
15 Jun 2022
28
Days
0
Hrs
22
Min
Register

Optimizing mRNA purification conditions by using a Design of Experiments...

J England
Jenny England
Jenny England
Application Scientist and Innovation Leader at Thermo Fisher Scientific
14 Jun 2022
27
Days
0
Hrs
22
Min
Register

Life on a chip - vascularized micro-tumor chips for mimicking clinical...

C Hughes
Chris Hughes
Chris Hughes
CSO at Aracari Biosciences
8 Jun 2022
21
Days
0
Hrs
22
Min
Register